Overall survival of patients with KIT-mutant metastatic GIST in the era of multiple kinase inhibitor availability

• DOI: 10.1007/s00432-024-05965-2
• Publication Date: 2024-11-09T03:32:00Z
• Authors: Valerie Haller; Carina Reiff; Rainer Hamacher; Karina Kostbade; Moritz Kaths; Juergen Treckmann; Stefanie Bertram; Yasmin Zaun; Sebastian Bauer; Johanna Falkenhorst
• Keywords: Hematology

The prognosis of patients with metastatic GIST and imatinib-sensitive primary mutations has significantly improved. However, limited data are available to inform about outcomes across different lines treatment. This retrospective analysis aims evaluate patient at a large German referral center over the past 15 years.